On 8 June 2026, the European Medicines Agency (EMA) published the minutes of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting held from 7 to 10 April 2026. The document summarises the committee's discussions on the safety of several medicines, including recommendations for updates to product information and risk management plans. The minutes are a routine publication that provides transparency on PRAC's decision-making process, impacting pharmaceutical companies, healthcare professionals, and patients who rely on EMA's safety assessments.
The PRAC meeting covered a range of topics, including the review of periodic safety update reports (PSURs) for several active substances, signal detection and evaluation, and the assessment of risk management plans (RMPs). The committee adopted recommendations for updates to the product information of certain medicines, such as adding new warnings or precautions for use. These recommendations are non-binding but are typically followed by the European Commission when making final regulatory decisions.
Document metadata: The minutes were published by EMA's Pharmacovigilance Risk Assessment Committee, dated 8 June 2026, covering the meeting of 7-10 April 2026. The document is a formal record of the committee's proceedings and decisions.
Policy orientations and trade-offs: The PRAC's work balances patient safety with ensuring continued access to medicines. Recommendations to update product information may impose additional monitoring requirements on marketing authorisation holders, but they aim to mitigate risks identified through pharmacovigilance data. The committee also discussed the need for further studies or risk minimisation measures for certain products, reflecting a precautionary approach to emerging safety signals.
Impact on stakeholders: Pharmaceutical companies may face costs related to implementing new safety measures or updating labelling. Healthcare professionals will receive updated guidance on prescribing and monitoring. Patients benefit from enhanced safety information but may experience changes in treatment options if restrictions are recommended. National competent authorities use PRAC recommendations to inform their own pharmacovigilance activities.
Expected institutional follow-up: The PRAC recommendations will be forwarded to the European Commission for adoption, and marketing authorisation holders are expected to implement the agreed changes within specified timelines. The next PRAC meeting is scheduled for May 2026, and further updates will be published in subsequent minutes.